Wound healing ILYA-style 2

Project description

Proprietary dressings for the treatment of chronic wounds

Treatment of non-healing chronic wounds represents an unmet clinical need with conventional wound dressings failing to protect against recurrent infections, leading to increased mortality. The rising incidence of diabetes and obesity alongside antibiotic resistance exacerbate the situation. The EU-funded WHILYAS-2 project proposes to address the insufficient treatment of chronic wounds through a proprietary technology that utilises chemokines as therapeutic agents through local administration from genetically modified lactic acid bacteria. For clinical proof of concept, partners will conduct a phase II clinical trial of their drug candidate ILP100 Topical in patients with diabetes.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• medical and health sciences › health sciences › public health › epidemiology › pandemics
• medical and health sciences › clinical medicine › endocrinology › diabetes
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antibiotics
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › antibiotic resistance

Programme(s)

• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020-3
See other projects for this call

Funding Scheme

SME-2b - SME Instrument (grant only and blended finance)

Coordinator

ILYA PHARMA AB

Address

Dag Hammarskiolds Vag 30
752 37 Uppsala
Sweden

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

EU contribution

€ 1 360 362